Literature DB >> 24908563

Seizure and radiological outcomes in children with solitary cysticercous granulomas with and without albendazole therapy: a retrospective case record analysis.

Sheffali Gulati1, Puneet Jain2, Deepak Sachan3, Biswaroop Chakrabarty4, Atin Kumar5, R M Pandey6, Arun K Gupta7.   

Abstract

Neurocysticercosis, parasitic infestation of the central nervous system by the Taenia solium larvae, is a major public health problem, primarily in the developing countries. Seizures are the primary clinical manifestation which could be acute (secondary to active lesions) or remote symptomatic (due to calcified lesions). Cysticidal therapy is the standard of care for solitary parenchymal active neurocysticerci. However treatment related side effects and tendency to spontaneous resolution raises concern from time to time whether cysticidal therapy is actually required. This is a retrospective case record analysis of two groups of patients with solitary parenchymal neurocysticerci (group A; 171 patients between 2000 and 2004 who did not receive cysticidal therapy, group B; 512 patients between 2008 and 2013 who received cysticidal therapy). Group B had significantly more radiological resolution of lesions whereas group A reported significantly more seizure recurrences on antiepileptics. There was no significant difference in occurrence of calcification in the two groups. Overall patients with calcified lesions had significantly more breakthrough seizures. Well designed prospective studies should be planned in future to understand the mechanism underlying the epileptogenicity of calcified lesions and how they are linked to host and environment factors.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Albendazole; Calcification; Epilepsy; Neurocysticercosis; Perilesional edema

Mesh:

Substances:

Year:  2014        PMID: 24908563     DOI: 10.1016/j.eplepsyres.2014.04.013

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  7 in total

1.  Exploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis.

Authors:  Arturo Carpio; Mindy Chang; Hongbin Zhang; Matthew L Romo; Alex Jaramillo; W Allen Hauser; Elizabeth A Kelvin
Journal:  Epilepsia       Date:  2019-07-29       Impact factor: 5.864

2.  An Ambispective Cohort Study to Assess Seizure Recurrences in Children with Calcified Parenchymal Neurocysticercosis.

Authors:  Abhijit Modak; Renu Suthar; Indar Kumar Sharawat; Naveen Sankhyan; Jitendra Kumar Sahu; Prahbhjot Malhi; Niranjan Khandelwal
Journal:  Am J Trop Med Hyg       Date:  2019-10       Impact factor: 2.345

3.  A longitudinal analysis of albendazole treatment effect on neurocysticercosis cyst evolution using multistate models.

Authors:  Michelle A Montgomery; Marcel Ramos; Elizabeth A Kelvin; Arturo Carpio; Alexander Jaramillo; W Allen Hauser; Hongbin Zhang
Journal:  Trans R Soc Trop Med Hyg       Date:  2019-12-01       Impact factor: 2.184

4.  CystiHuman: A model of human neurocysticercosis.

Authors:  Gabrielle Bonnet; Francesco Pizzitutti; Eloy A Gonzales-Gustavson; Sarah Gabriël; William K Pan; Hector H Garcia; Javier A Bustos; Percy Vilchez; Seth E O'Neal
Journal:  PLoS Comput Biol       Date:  2022-05-19       Impact factor: 4.779

Review 5.  Taenia solium Cysticercosis and Its Impact in Neurological Disease.

Authors:  Hector H Garcia; Armando E Gonzalez; Robert H Gilman
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

6.  Prevalence, Response to Cysticidal Therapy, and Risk Factors for Persistent Seizure in Indian Children with Neurocysticercosis.

Authors:  Animesh Kumar; Anirban Mandal; Sheela Sinha; Amitabh Singh; Rashmi Ranjan Das
Journal:  Int J Pediatr       Date:  2017-01-10

7.  Neurocysticercosis in patients with active epilepsy in the tea garden community of Assam, Northeast India.

Authors:  K Rekha Devi; Debasish Borbora; Narayan Upadhyay; Dibyajyoti Goswami; S K Rajguru; Kanwar Narain
Journal:  Sci Rep       Date:  2021-04-01       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.